

About Deep Pharma Intelligence

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

Deep Pharma Intelligence is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** – two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment analytics. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

Our Value Proposition:

Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets – technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.


IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our prototype dashboard to learn more:
<https://www.deep-pharma.tech/dashboard>

Strategic Consulting and Investment Analytics

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.




AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020

The 130-page analytical Report and interactive analytics Dashboard “AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020” delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and Big Data analytical Dashboard.

The current release includes insights about **240+ biotech companies, 600+ investors, 90+ pharma corporations, and 35 R&D centers** in the area of pharmaceutical and healthcare artificial intelligence (AI).


Some of the key takeaways from this report include:

- The segment of pharmaceutical AI continues consolidation;
- Pharmaceutical AI sector is “heating up” for investments;
- Big pharma and contract research organizations increasingly compete for AI partnerships;
- The sector of pharmaceutical AI is maturing for a likely wave of IPOs and M&As in 2021-2022;
- COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption



AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2020



Pharma AI Deals Structure 2020

AI Companies			
Exscientia	Atomwise	turbine	CYCLICA
saama	5	XtalPi	Biovista
BERG	Alibaba Group	Tencent 腾讯	
FOUNDATION MEDICINE	RECURSION	Insilico Medicine 英科智能	WAVE
BioSymetrics	RESONANT	DATAVANT	
ReverieLabs	Genialis	Exscientia	
Atomwise	IKTOS	CYCLICA	
sirenas	Concerto HealthAI	e-therapeutics	
	turbine		